OR-25 - PREVALÊNCIA DA INFECÇÃO LATENTE POR TUBERCULOSE EM PESSOAS IDOSAS QUE VIVEM COM HIV: INSIGHTS DA COORTE ELEA-BRASIL

Autor: Roberta Schiavon Nogueira, Jose Valdez Ramalho Madruga, Camila Rodrigues, Paridhi Ranadive, Vivian I. Avelino-Silva, Marilia Bordignon Antonio, Carlos Roberto Brites, Sandra Wagner Cardosos, Jessica L. Castilho, Beatriz Grinsztejn

Publikováno v: Brazilian Journal of Infectious Diseases, Vol 28, Iss , Pp 103900- (2024)

Introdução: Estima-se que 1/4 da população mundial esteja infectada com Mycobacterium tuberculosis, com maior risco de doença concentrado nos primeiros anos após a infecção primária, porém o período de latência pode durar anos. Tanto a in

Externí odkaz: https://doaj.org/article/75a3c0a57a094553a5a4d36a0b08f1e6

Contextualizing and optimizing novel strategies to improve the latent TB continuum of care: Insights from people living with HIV and health care providers in Brazil.

Autor: Isadora Salles, Paula Travassos, Renata Spener-Gomes, Ana Paula Loch, Valeria Saraceni, Lilian Lauria, Solange Cavalcante, Jamile Garcia de Oliveira, Alexandra Brito de Souza, Allyson Guimarães Costa, Sumire Sakabe, Roberta Schiavon Nogueira, Lelia H Chaisson, Silvia Cohn, Leda Fatima Jamal, Jose Valdez Ramalho Madruga, Marcelo Cordeiro-Santos, Barbara Castro, Danielle Portella Ferreira, Christopher J Hoffmann, Jonathan E Golub, Betina Durovni, Deanna Kerrigan

Publikováno v: PLOS Global Public Health, Vol 3, Iss 1, p e0001251 (2023)

Tuberculosis (TB) causes 1 in 3 deaths among people living with HIV (PLHIV). Diagnosing and treating latent tuberculosis infection (LTBI) is critical to reducing TB incidence and mortality. Blood-based screening tests (e.g., QuantiFERON-TB Gold Plus

Externí odkaz: https://doaj.org/article/62ee98f56ef94a04bc9cec613e14abd0

Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period

Autor: Boccara, Franck, Caramelli, Bruno, Calmy, Alexandra, Kumar, Princy, López, J Antonio G, Bray, Sarah, Cyrille, Marcoli, Rosenson, Robert, S Australia: David Baker, Mark, Bloch, Robert, Finlayson, Jennifer, Hoy, Kenneth, Koh, Norman, Roth, Belgium: Stephane De Wit, Eric, Florence, Linos, Vandekerckhove, Brazil: Bruno Caramelli, Jose Valdez Ramalho Madruga, Sandra Wagner Cardoso, Canada: Greg Bondy, Michael, Gill, George, Tsoukas, Sylvie, Trottier, Marek, Smieja, France: Franck Boccara, Christine, Katlama, Fabrice, Bonnet, Francois, Raffi, Laurent, Cotte, Jean-Michel, Molina, Jacques, Reynes, Greece: Antonios Papadopoulos, Simeon, Metallidis, Vassilios, Paparizos, Vasileios, Papastamopoulos, Italy: Cristina Mussini, Massimo, Galli, Andrea, Antinori, DI BIAGIO, Antonio, Pierluigi, Viale, Poland: Andrzej Horban, Portugal: Nuno Marques, Daniel, Coutinho, Joaquim, Oliveira, Paula, Freitas, Romania: Liliana-Lucia Preotescu, Iosif, Marincu, Rodica, Silaghi, Sorin, Rugina, South Africa: Noluthando Mwelase, Sheena Kotze, Spain: Jose Ignacio Bernardino de la Serna, Vicente Estrada Perez, Esteban, Martinez, Adrian, Curran, Switzerland: Dominique Laurent Braun, Alexandra, Calmy, Enos, Bernasconi, Matthias, Cavassini, United Kingdom: John Walsh, Julie, Fox, Graeme, Moyle, United States: Robert Rosenson, Jamie, Morano, Jason, Baker, Gerald, Pierone, Carl, Fichtenbaum, Paul, Benson, Deborah, Goldstein, Joseph, Sacco, Princy, Kumar, Robert, Grossberg, Kara, Chew, Christopher, Defilippi, Vilma, Drelichman, Norman, Markowitz, David, Parenti, Katherine, Doktor, Paul, Thompson.

People with HIV (PWH) are at an increased risk of atherosclerotic cardiovascular disease. Suboptimal responses to statin therapy in PWH may result from antiretroviral therapies (ARTs). This open-label extension study aimed to evaluate the long-term s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::421d22bf119a8ac1c02242939c2e4e3f
http://hdl.handle.net/11567/1074656

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis

Autor: Henrique Sérgio Moraes Coelho, Mário Reis Álvares-da-Silva, Ana de Lourdes Candolo Martinelli, Carlos Eduardo Brandão-Mello, Giovanni Faria Silva, Raymundo Paraná, Sara A. Lari, Hugo Cheinquer, Rakesh Tripathi, Li Liu, Maria Lucia Gomes Ferraz, Jose Valdez Ramalho-Madruga, Estevão P. Nunes, Mario G. Pessoa, Evaldo S. Affonso-de-Araújo, Tami Pilot-Matias, Paulo Roberto Abrão Ferreira, Juvencio Furtado, Katia Alves, Maria Cassia Mendes-Correa, Nancy S. Shulman, Daniel E. Cohen

Publikováno v: Annals of Hepatology, Vol 17, Iss 6, Pp 959-968 (2018)

Introduction and aim: Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1a6d9bbc24c7fe83070999b4e12120
http://www.sciencedirect.com/science/article/pii/S1665268119310580

Raltegravir once daily or twice daily in previously untreated patients with HIV-1:A randomised, active-controlled, phase 3 non-inferiority trial

Autor: Eron, Joseph J., Rockstroh, Jurgen K., Jacques, Reynes, Jaime Andrade Villanueva, Jose Valdez Ramalho Madruga, Linda Gail Bekker, Benjamin, Young, Christine, Katlama, Jose Maria Gatell Artigas, Arribas, Jose R., Mark, Nelson, Havilland, Campbell, Jing, Zhao, Rodgers, Anthony J., Rizk, Matthew L., Larissa, Wenning, Miller, Michael D., Daria, Hazuda, Dinubile, Mark J., Randi, Leavitt, Robin, Isaacs, Robertson, Michael N., Peter, Sklar, Bach Yen Nguyen, Mezzaroma, Ivano, Italy, Rome

Publikováno v: Eron, J J, Rockstroh, J K, Reynes, J, Andrade-Villanueva, J, Ramalho-Madruga, J V, Bekker, L G, Young, B, Katlama, C, Gatell-Artigas, J M, Arribas, J R, Nelson, M, Campbell, H, Zhao, J, Rodgers, A J, Rizk, M L, Wenning, L, Miller, M D, Hazuda, D, DiNubile, M J, Leavitt, R, Isaacs, R, Robertson, M N, Sklar, P, Nguyen, B Y, Laursen, A L & QDMRK Investigators 2011, ' Raltegravir once daily or twice daily in previously untreated patients with HIV-1 : A randomised, active-controlled, phase 3 non-inferiority trial ', The Lancet Infectious Diseases, vol. 11, no. 12, pp. 907-915 . https://doi.org/10.1016/S1473-3099(11)70196-7
Lancet infectious diseases, 11(12), 907-915. Lancet Publishing Group

Background: Twice-daily raltegravir with once-daily tenofovir-emtricitabine is an effective initial antiretroviral regimen for patients with HIV-1. On the basis of pharmacokinetic data suggesting efficacy of once-daily raltegravir and because adheren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72d45694a6e3952a234f3eea634809c3
https://pure.au.dk/portal/da/publications/raltegravir-once-daily-or-twice-daily-in-previously-untreated-patients-with-hiv1(6e27858b-c904-4f40-96e7-c40413c95477).html